Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis ; volume:10 ; number:3 ; day:7 ; month:5 ; year:2008 ; pages:1-6 ; date:6.2008
Arthritis Research & Therapy ; 10, Heft 3 (7.5.2008), 1-6, 6.2008
- Urheber
-
Atzeni, Fabiola
- Beteiligte Personen und Organisationen
-
Sarzi-Puttini, Piercarlo
Lama, Nicola
Bonacci, Eleonora
Bobbio-Pallavicini, Francesca
Montecucco, Carlomaurizio
Caporali, Roberto
SpringerLink (Online service)
- DOI
-
10.1186/ar2420
- URN
-
urn:nbn:de:1111-201605039608
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Atzeni, Fabiola
- Sarzi-Puttini, Piercarlo
- Lama, Nicola
- Bonacci, Eleonora
- Bobbio-Pallavicini, Francesca
- Montecucco, Carlomaurizio
- Caporali, Roberto
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis
Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis
Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis
Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis
Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study
Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?
Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis
Response to `Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study'
Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study
Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides
Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis
Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis
Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis
Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis
Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis
Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis
Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study
Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?
Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis
Response to `Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study'
Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study
Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides
Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis
Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis
Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis
Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis
Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis
Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis
Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study
Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?
Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis
Response to `Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study'
Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study
Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides
Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis